Literature DB >> 7115651

Ocular changes resulting from therapy with amiodarone.

D V Ingram, N S Jaggarao, D A Chamberlain.   

Abstract

Amiodarone, a powerful antiarrhythmic agent recently made available in Britain, is known to cause corneal changes, but the clinical implications of this unwanted effect are still controversial. We have made serial observations on 105 patients treated with the drug for periods ranging from 3 months to over 7 years. Corneal abnormalities were detected by slit-lamp examination in 103 patients (98%). These always progressed over several months but subsequently showed a stable pattern which changed only with alteration of dose. The abnormalities regressed and disappeared within 7 months in the 16 patients whose treatment was discontinued for reasons unconnected with ocular changes. No macular changes or permanent sequelae occurred. Ocular symptoms were unusual: 6 patients had reactions in the skin of the eyelids, and 6 others had minor symptoms related to the corneal changes. We do not believe that ophthalmological surveillance is mandatory in asymptomatic patients on long-term amiodarone therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115651      PMCID: PMC1039895          DOI: 10.1136/bjo.66.10.676

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Untoward effects associated with practolol administration: oculomucocutaneous syndrome.

Authors:  P Wright
Journal:  Br Med J       Date:  1975-03-15

2.  The ocular complications of chloroquine therapy.

Authors:  H E HOBBS; C D CALNAN
Journal:  Lancet       Date:  1958-06-07       Impact factor: 79.321

3.  "BLUE HALOES" IN ATEBRIN WORKERS.

Authors:  I Mann
Journal:  Br J Ophthalmol       Date:  1947-01       Impact factor: 4.638

4.  [Corneal thesaurismosis due to amiodarone. Current data].

Authors:  P Vérin; P Gendre; G Barchewitz; G Laurent-Bronchat; M Yacoubi; S Morax
Journal:  Arch Ophtalmol Rev Gen Ophtalmol       Date:  1971 Aug-Sep

5.  [Iatrogenic ocular lesions; action of a new medicament against angor pectoris].

Authors:  J Babel; N Stangos
Journal:  Arch Ophtalmol Rev Gen Ophtalmol       Date:  1970-03

6.  Cornea verticillata.

Authors:  J François
Journal:  Doc Ophthalmol       Date:  1969       Impact factor: 2.379

Review 7.  Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone.

Authors:  F I Marcus; G H Fontaine; R Frank; Y Grosgogeat
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

8.  Vortex patterns of the corneal epithelium.

Authors:  A J Bron
Journal:  Trans Ophthalmol Soc U K       Date:  1973

9.  Eye and skin changes in psychiatric patients treated with chlorpromazine.

Authors:  M B Mathalone
Journal:  Br J Ophthalmol       Date:  1967-02       Impact factor: 4.638

10.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

View more
  16 in total

1.  In vivo confocal microscopy in hydroxychloroquine-induced keratopathy.

Authors:  André Dosso; Elisabeth Rungger-Brändle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

Review 3.  Amiodarone-Associated Optic Neuropathy: Clinical Review.

Authors:  An-Guor Wang; Hui-Chen Cheng
Journal:  Neuroophthalmology       Date:  2016-11-18

Review 4.  Amiodarone: the experience of the past decade.

Authors:  W J McKenna; E Rowland; D M Krikler
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

Review 5.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09

Review 6.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

7.  Absence of bilateral vision loss from amiodarone: a randomized trial.

Authors:  Joel S Mindel; Jill Anderson; Anne Hellkamp; George Johnson; Jeanne E Poole; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  Am Heart J       Date:  2007-05       Impact factor: 4.749

8.  Progression of amiodarone induced cataracts.

Authors:  A J Flach; B J Dolan
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

Review 9.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 10.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.